CLINICAL REPORTS

Blood dyscrasias and mianserin

P. C. ADAMS
B.A., M.R.C.P.

M. M. REID
M.D., M.R.C.P.

ANGELA ROBINSON
M.B.

M. C. VISHU*
M.D., M.R.C.P.

M. LIVINGSTON†
M.B., M.R.C.Psych.

Departments of Medicine and Haematology, Royal Victoria Infirmary, Newcastle upon Tyne,
*Department of Medicine, Cumberland Infirmary, Carlisle and
†University Department of Psychological Medicine, Gartnavel Royal Hospital,
1053 Great Western Road, Glasgow

Summary

Four cases are described in which the drug mianserin was implicated in the development of leucopenia. In one case this was accompanied by fatal aplastic anaemia. In a second, generalized bone marrow depression occurred, although leucopenia was the only clinically significant manifestation. Mianserin may depress bone marrow function and haematological surveillance is appropriate for patients taking this drug.

KEY WORDS: mianserin, leucopenia, bone marrow.

Blood dyscrasias and mianserin

The tetracyclic antidepressant mianserin is now widely prescribed, particularly in the elderly. Adverse reactions are generally few and no fatality has previously been reported with its use. We have seen four cases in which blood dyscrasias developed in patients being treated with mianserin. There was evidence of recovery in all after mianserin was discontinued but, unfortunately, one patient died.

Case reports

Case 1

A 52-year-old woman presented with an eight day history of bruising, bleeding gums and epistaxis, and malaise for three days. Twelve weeks before admission she had taken an overdose of salbutamol tablets. Two weeks later treatment with mianserin 30 mg at night was started for symptoms of anxiety and depression. Poor compliance was suspected and she was admitted to a psychiatric unit where she received mianserin 90 mg at night, with temazepam 20 mg at night and occasional paracetamol. Her blood count on admission to the psychiatric unit was normal. She received no other treatment and had had no other illnesses in the three months before presentation.

On examination she was pale with widespread petechiae. She was febrile and had signs of a left basal pneumonia, confirmed by chest radiography. Haemoglobin was 7-7 g/dl, with normal indices, white cell count 0-6 × 10⁹/litre, of which 1% were neutrophils and 99% lymphocytes. Platelets were less than 10 × 10⁹/litre. Bone marrow smears were very hypocellular, the only nucleated cells present being lymphocytes. Trephine biopsy revealed a very hypoplastic marrow, the majority of cells being erythroid and lymphoid. No megakaryocytes were seen.

Mianserin and temazepam were withdrawn and she was treated with gentamicin, fluclaxacillin, penicillin and metronidazole, with resolution of her temperature. No fresh bleeding occurred so she received a blood transfusion only. Unfortunately, a fatal intracranial haemorrhage occurred suddenly five days after admission. The day before death her leucocyte count had risen to 6-9 × 10⁹/litre, suggesting her marrow had begun to recover. However, the
Clinical reports

post-mortem marrow histology was still markedly hypoplastic.

Case 2

A 69-year-old man presented with twelve days of pyrexia, rigors and oral ulceration. Eight weeks previously 'evolutional melancholia' had been diagnosed, and he was treated with mianserin 30 mg three times a day and 90 mg at night with good effect. Full physical examination and blood count were normal at that time. He had had no other illnesses and had only received nitrazepam 20 mg at night in addition to the mianserin in the three months before admission. On admission the temperature was 38·5°C, there were oral ulcers and petechiae but no other abnormal physical signs. Haemoglobin was 12·7 g/dl, with normal indices, white cell count 0·6×10⁹/litre, with neutropenia; 2% neutrophils, 89% lymphocytes, 5% monocytes, 3% eosinophils and 1% basophils. The platelet count was 330×10⁹/l. Bone marrow smears were hypocellular and were devoid of neutrophils and megakaryocytes. Trephine biopsy revealed marrow spaces containing virtually no haemopoietic cells. Occasional bone marrow fragments contained more erythroid and lymphoid cells and occasional megakaryocytes, but very few myeloid cells. Mianserin and nitrazepam were discontinued and he improved rapidly on gentamicin, ticarcillin and metronidazole. After five days he was afebrile and at eleven days his blood count was normal with a leucocyte count of 5·0×10⁹/litre, with 68% neutrophils. At follow-up four weeks later he was well. No known cause of marrow suppression was revealed by full investigation.

Case 3

A 41-year-old woman had been prescribed mianserin 20 mg at night, and clobazam 10 mg three times daily. Five weeks later she presented to her general practitioner with a one day history of fever, generalized aches and pains and a sore throat. She had marked cervical lymphadenopathy with inflamed pharyngeal and tonsillar walls, and was febrile. Cotrimoxazole, 2 tablets twice daily, was prescribed, and the next day, having taken no more than four cotrimoxazole tablets, a full blood count was performed which revealed an absolute neutropenia. She was admitted to hospital on the same day, where no other abnormal physical signs were detected. Full blood count in hospital revealed a haemoglobin of 11·5 g/dl, with normal indices. The total leucocyte count was 1·1×10⁹/litre, with 2% neutrophils, 6% eosinophils, 45% lymphocytes and 47% monocytes. The platelet count was 216×10⁹/l. Mianserin, clobazam and cotrimoxazole were discontinued and five days later the white cell count was 3·6×10⁹/litre, of which 23% were neutrophils, 12% monocytes, 6% eosinophils and 59% lymphocytes. Four days later the white count was 5·4×10⁹/litre, of which 50% were neutrophils. The return of the white cell count to normal was accompanied by complete recovery. There was no evidence of any other known cause of agranulocytosis and there have been no major clinical developments since her discharge from hospital.

Case 4

A 68-year-old woman presented with persistent occipital and frontal headache and symptoms suggestive of a primary depressive illness. No organic cause was found for the headache and mianserin 30 mg at night was given. This was increased to 60 mg at night three weeks later. Other therapy was gliceryl trinitrate 600 µg sublingually as needed and butobarbitone 200 mg at night as an hypnotic. She had had a myocardial infarction five years before and also complained of persistent dyspepsia.

After five weeks treatment with mianserin, full blood count demonstrated a total white count of 2·0×10⁹/litre, of which 7% were neutrophils, 75% lymphocytes and 18% monocytes. Haemoglobin was 9·6 g/dl, with iron deficient indices. The platelet count was judged 'adequate' on film appearances. Her blood count five years before was normal, although three years before mild iron deficiency had been demonstrated. In view of her neutropenia mianserin was discontinued. Two weeks later her leucocyte count was 3·7×10⁹/litre, with 46% neutrophils, 51% lymphocytes and the remainder basophils and monocytes. A month later it had risen to 5·9×10⁹/litre of which 49% were neutrophils. Haemoglobin was still 9·4 g/dl. Unfortunately, the patient failed to attend for further appointments and was lost to hospital follow-up. No major problem has been notified to her general practitioner to date, however.

Discussion

In Case 1, all marrow elements were depressed. Thrombocytopenia was responsible for her death. After stopping mianserin there was a rise in the total leucocyte count suggesting some marrow recovery before death. There was no evidence of any systemic disease or other blood dyscrasia at post-mortem examination and cultures of blood, sputum, urine and multiple skin sites were sterile or only showed normal flora, suggesting that overwhelming infection was an unlikely cause of her marrow depression. There was no evidence of viral hepatitis; post-mortem liver histology was normal. It seems likely that mianserin caused her aplastic anaemia.

In Cases 2 and 3, the clinical presentation was fairly typical of agranulocytosis. However, in Case 2,
marrow appearances again showed depression of both erythroid and megakaryocyte lines and we wonder if continued exposure would have produced pancytopenia as in Case 1. Both patients recovered promptly on drug withdrawal. The only other drugs which could be implicated were benzodiazepines, and there is little evidence, despite massive worldwide use, that these agents can cause marrow suppression.

In Case 3, only four tablets of cotrimoxazole were taken before neutropenia was established, and it is highly unlikely that such profound neutropenia could have been caused so rapidly by this drug. We feel it likely, therefore, that mianserin was responsible for the neutropenia. Neutropenia undoubtedly occurred in Case 4 but fortunately caused no clinical problems. It again responded well to mianserin withdrawal. We did not feel re-challenge was appropriate in any of those cases and the evidence incriminating mianserin must, therefore remain circumstantial.

In six previous published cases, neutropenia had been ascribed to mianserin therapy (Curson and Hale, 1979; McHarg and McHarg, 1979; Adverse Drug Reactions Advisory Committee (of Australia), 1980). In two of these cases phenothiazines were also taken, although in one, the drug in question, prochlorperazine, was re-instated with no further fall in leucocyte count. The Committee on Safety of Medicines has received reports of seven other cases of neutropenia occurring in patients receiving mianserin (Committee on Safety of Medicines, 1981a). In four of these there was thought to be a strong probability that the reaction was due to mianserin therapy. The reaction has been highlighted in a recent 'Current Problems' (Committee on Safety of Medicines, 1981b).

Mianserin is used widely in both hospital and general practice. Side effects of the severity described here demand that all patients receiving this drug should be followed carefully, with scrupulous attention being paid to the results of regular blood counts. Our experience underlines the importance of continued reporting of side effects of new drugs and reinforces the possibility that serious problems may arise with apparently safe substances. Careful reporting of all suspected adverse drug reactions to the Committee on Safety of Medicines remains the most reliable way of identifying adverse reactions which occur at low frequency, particularly when they mimic naturally occurring disease.

Acknowledgments

We would like to thank Dr D. W. Zutshi for his help and also the consultants under whose care these patients came. Thanks are also due to Mrs D. Naisby for invaluable secretarial assistance.

References

Committee on Safety of Medicines (1981a) Personal Communication.

(Accepted 7 April 1982)
Blood dyscrasias and mianserin.

P. C. Adams, A. Robinson, M. M. Reid, M. C. Vishu and M. Livingston

Postgrad Med J 1983 59: 31-33
doi: 10.1136/pgmj.59.687.31

Updated information and services can be found at:

http://pmj.bmj.com/content/59/687/31

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/